Ovarian Stimulation Drugs Not Tied to Higher Breast Cancer Risk

THURSDAY, July 1, 2021 -- Women treated with ovarian stimulation drugs for infertility do not have a significantly increased risk of breast cancer, according to a systematic review and meta-analysis published in the July issue of Fertility and...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

AbstractStudy questionDo different types of cancer affect the success of oocyte maturation in vitro compared to infertile women included in the in vitro fertilization (IVF) program?Summary answerCancer does not adversely affect oocyte maturation in vitro, with the exception of breast cancer, compared to infertile women in the in vitro fertilization program.What is known alreadyVitrification and storage of oocytes in liquid nitrogen is one of the real options for maintaining reproductive function in cancer patients. Despite careful hormonal stimulation of the ovaries, however, the proportion of oocytes is immature and lost ...
Source: Human Reproduction - Category: Reproduction Medicine Source Type: research
J Clin Endocrinol Metab. 2021 Jun 22:dgab461. doi: 10.1210/clinem/dgab461. Online ahead of print.ABSTRACTCONTEXT: In a previous study we reported that anti-Müllerian hormone (AMH), a marker of ovarian reserve, is positively associated with breast cancer risk, consistent with other studies.OBJECTIVE: Assess whether risk factors for breast cancer are correlates of AMH concentration.DESIGN: Cross-sectional.PARTICIPANTS: 3831 healthy premenopausal women (aged 21-57, 87% aged 35-49).SETTING: Ten cohort studies, general population.RESULTS: Adjusting for age and cohort, we observed positive associations of AMH with age at menarche (p
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Source Type: research
J Clin Endocrinol Metab. 2021 Jun 22:dgab461. doi: 10.1210/clinem/dgab461. Online ahead of print.ABSTRACTCONTEXT: In a previous study we reported that anti-Müllerian hormone (AMH), a marker of ovarian reserve, is positively associated with breast cancer risk, consistent with other studies.OBJECTIVE: Assess whether risk factors for breast cancer are correlates of AMH concentration.DESIGN: Cross-sectional.PARTICIPANTS: 3831 healthy premenopausal women (aged 21-57, 87% aged 35-49).SETTING: Ten cohort studies, general population.RESULTS: Adjusting for age and cohort, we observed positive associations of AMH with age at menarche (p
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
There was no significant increase in the risk of breast cancer among women treated with any ovarian stimulation drug for infertility, say King's College London scientists.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
CONCLUSIONS: By facilitating referral and seeking funds and special discounts for underserved patients, supportive care programs for young women with breast cancer can play a crucial role on enhancing access to oncofertility services that would otherwise be prohibitive because of their high costs, particularly in resource-constrained settings. For these efforts to be successful and widely applied in the long term, sustained and extended governmental coverage of FP options for this young group is warranted.PMID:34153944 | DOI:10.6004/jnccn.2020.7692
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Authors: Source Type: research
To evaluate the evidence addressing the association between the use of ovarian stimulation drugs and the risk of breast cancer.
Source: Fertility and Sterility - Category: Reproduction Medicine Authors: Tags: Original article Source Type: research
ConclusionAmenorrhea at 18  months was less likely in recipients of adjuvant T-DM1 than TH. Future studies are needed to understand how T-DM1 impacts risk of infertility and permanent menopause, and to assess amenorrhea rates when T-DM1 is administered after standard HER2-directed chemotherapy regimens.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsMore than 90% of premenopausal women with early breast cancer, and particularly those with hormone receptor-positive disease, were concerned about the potential risk of chemotherapy-induced premature ovarian insufficiency and/or infertility and accepted GnRHa administration. Less than 1 out of 5 women aged ≤40 years accepted to undergo cryopreservation strategies.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In this report, menopausal symptoms related to anti-cancer treatment are described. Menstrual disturbances associated with the use of adjuvant chemotherapy, endocrine therapy and targeted therapy against human epidermal growth factor receptor 2 (HER2) in premenopausal women with BC are discussed. To prevent menopausal symptoms, CRA and POI, data on the efficacy of temporary ovarian suppression with gonadotropin-releasing hormone analogues (GnRHa) during chemotherapy are highlighted. Pooled analyses have confirmed that concurrent administration of GnRHa during chemotherapy could significantly reduce the risk of developing c...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research
This study aimed to investigate young adult cancer patients' receipt of fertility-related information and use of fertility preservation, and to identify sociodemographic and clinical factors associated with receipt of information.MATERIALS AND METHODS: A population-based cross-sectional survey study was conducted with 1010 young adults with cancer in Sweden (response rate 67%). The inclusion criteria were: a previous diagnosis of breast cancer, cervical cancer, ovarian cancer, brain tumor, lymphoma or testicular cancer between 2016 and 2017, at an age between 18 and 39 years. Data were analyzed using logistic regression mo...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Infertility | Ovarian Cancer | Ovaries | Pharmaceuticals | Reproduction Medicine | Women